Literature DB >> 31454051

Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions.

Gil Yosipovitch1, Laurent Misery, Ehrhardt Proksch, Martin Metz, Sonja Ständer, Martin Schmelz.   

Abstract

Barrier damage, dry skin and itch are intricately linked and form the basis of many common skin diseases. Damage from environmental insults, or genetic or inflammatory causes, can impair the skin barrier, resulting in an increase in transepidermal water loss and activation of itch-associated nerve fibres. The itch-scratch cycle can perpetuate skin barrier damage and itch. Topical therapeutic strategies are utilised to overcome dry skin and itch, primarily in the form of emollients. Recent advances in our understanding of the mechanisms underlying itch have enabled the development of new topical therapies, which may be incorporated into existing treatment regimes. Ultimately, treatment of dry skin and itch must be highly tailored to the individual according to their needs.

Entities:  

Keywords:  dry skin; emollients; skin barrier; pruritus

Mesh:

Substances:

Year:  2019        PMID: 31454051     DOI: 10.2340/00015555-3296

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  18 in total

Review 1.  THE SKIN MICROBIOTA AND ITCH: Is There a Link?

Authors:  Hei Sung Kim; Gil Yosipovitch
Journal:  J Clin Aesthet Dermatol       Date:  2020-06-01

2.  Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch.

Authors:  Johannes Wohlrab; David Stintzing; Luise Schultz; Konstantin Jügelt; Olaf H-U Schroeder
Journal:  Skin Pharmacol Physiol       Date:  2021-09-16       Impact factor: 3.479

Review 3.  Scabies: Epidemiology, Diagnosis, and Treatment.

Authors:  Cord Sunderkötter; Johannes Wohlrab; Henning Hamm
Journal:  Dtsch Arztebl Int       Date:  2021-10-15       Impact factor: 8.251

4.  Geriatric Skin Care in the Era of COVID-19.

Authors:  Rachel Shireen Golpanian; Gil Yosipovitch
Journal:  J Am Geriatr Soc       Date:  2020-06-07       Impact factor: 5.562

5.  Efficacy of a Topical Product Containing Purified Omental Lipids and Three Anti-Itching Compounds in the Treatment of Chronic Pruritus/Prurigo Nodularis in Elderly Subjects: A Prospective, Assessor-Blinded, 4-Week Trial with Transepidermal Water Loss and Optical Coherence Tomography Assessments.

Authors:  Marco Ardigò; Chiara Franceschini; Elena Campione; Terenzio Cosio; Caterina Lanna; Luca Bianchi; Massimo Milani
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-12-30

Review 6.  Intractable Itch in Atopic Dermatitis: Causes and Treatments.

Authors:  Yoshie Umehara; Chanisa Kiatsurayanon; Juan Valentin Trujillo-Paez; Panjit Chieosilapatham; Ge Peng; Hainan Yue; Hai Le Thanh Nguyen; Pu Song; Ko Okumura; Hideoki Ogawa; François Niyonsaba
Journal:  Biomedicines       Date:  2021-02-25

7.  The CysLT2R receptor mediates leukotriene C4-driven acute and chronic itch.

Authors:  Tiphaine Voisin; Caroline Perner; Marie-Angele Messou; Stephanie Shiers; Saltanat Ualiyeva; Yoshihide Kanaoka; Theodore J Price; Caroline L Sokol; Lora G Bankova; K Frank Austen; Isaac M Chiu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-30       Impact factor: 11.205

8.  Keratin 17 Is Required for Lipid Metabolism in Keratinocytes and Benefits Epidermal Permeability Barrier Homeostasis.

Authors:  Bingyu Pang; Zhenlai Zhu; Chunying Xiao; Yixin Luo; Hui Fang; Yaxing Bai; Zhongbin Sun; Jingyi Ma; Erle Dang; Gang Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-12

9.  MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway.

Authors:  Magda Babina; Zhao Wang; Saptarshi Roy; Sven Guhl; Kristin Franke; Metin Artuc; Hydar Ali; Torsten Zuberbier
Journal:  J Invest Dermatol       Date:  2020-10-13       Impact factor: 8.551

Review 10.  The Skin Microbiota and Itch: Is There a Link?

Authors:  Hei Sung Kim; Gil Yosipovitch
Journal:  J Clin Med       Date:  2020-04-22       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.